DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD.
Position in ANL — Adlai Nortye Group Ltd.
CIK 1672142
Singapore, U0
Position in ANL
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$103,800
New position
Shares Held
15,000
first reported quarter
Ownership
0.023%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. holds $13,369,286 across 13 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
5,546 | $2,754,864 | |
| 2 | IMVT |
Immunovant, Inc.
|
49,805 | $1,918,986 | |
| 3 | BNTX |
BioNTech SE
|
20,000 | $1,861,000 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
6,500 | $1,217,320 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
4,000 | $979,080 | |
| 6 | ERAS |
Erasca, Inc.
|
52,300 | $958,136 | |
| 7 | COGT |
Cogent Biosciences, Inc.
|
22,700 | $878,490 | |
| 8 | TRVI |
Trevi Therapeutics, Inc.
|
35,300 | $658,345 |
All Filings in ANL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $103,800 | 15,000 | Shares | Defined | 2026-05-14 | |
| No filing history on record for this holder in this stock. | ||||||